Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 3/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487211 | 1.00 | CYP3A4 (0.52) | CYP3A4CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| Hydrochloric Acid SCHEMBL4725966 | 0.98 | CSNK2A1 (0.53) | CYP3A4CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL17186331 | 0.83 | TAAR1 (0.67) | CYP3A4PNMTTAAR1ALDH1A1NPSR1 | |
| SCHEMBL3128100 | 0.82 | CSNK2A1 (0.47) | CSNK2A1CSNK2A2CSNK2BCSNK2A3PNMT | |
| SCHEMBL12107538 | 0.81 | CYP3A4 (0.54) | CYP3A4PNMTALDH1A1NPSR1KDM1A | |
| SCHEMBL8500210 | 0.79 | PNMT (0.52) | CYP3A4PNMTTAAR1ALDH1A1NPSR1 | |
| SCHEMBL30031076 | 0.79 | CYP3A4 (0.48) | CYP3A4PNMTALDH1A1NPSR1KDM1A | |
| SCHEMBL4026046 | 0.79 | CYP3A4 (0.48) | CYP3A4PNMTALDH1A1NPSR1KDM1A | |
| SCHEMBL1755262 | 0.79 | MAPT (0.49) | CYP3A4CSNK2A1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL112200 | 0.78 | PNMT (0.67) | CSNK2A1CSNK2A2CSNK2BCSNK2A3PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-1831206-B1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARM INC (US) | 2011-08-24 | — | — | EP | claimed |
| JP-2008521903-A | — | — | 2008-06-26 | — | — | JP | claimed |
| EP-1831206-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006060381-A2 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY | OSI PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | OSI PHARMACEUTICALS, INC. | 2006-06-01 | — | — | US | claimed |
| CN-1186332-C | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2005-01-26 | — | — | CN | claimed |
| CN-1337953-A | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2002-02-27 | — | — | CN | claimed |
| JP-5238995-A | — | — | None | — | — | JP | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2001030745-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| CN-1275124-A | Phthalazine derivatives and remedies for erectile dysfunction | EISAI CO LTD (JP) | 2000-11-29 | — | — | CN | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| JP-H05238995-A | N-BENZYL-N-PHENOXYETHYLAMINE AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE | MITSUBISHI GAS CHEM CO INC | 1993-09-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | CYP3A4 256/4885CSNK2A1 2216/4885CSNK2A2 2416/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CYP3A4 3128/4885CSNK2A1 57/4885CSNK2A2 29/4885 |
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, NUTF2 | CYP3A4 1214/4885CSNK2A1 1667/4885CSNK2A2 1003/4885 |
| US-20060116402-A1 | N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library | KIT, CHUK, TNNI3K | CYP3A4 3141/4885CSNK2A1 380/4885CSNK2A2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.